Beckman Coulter Names Scott Garrett CEO
Wareham's intention to retire in 2005 was disclosed early last year. Garrett's appointment is the result of a recommendation made by Beckman Coulter's board of directors' transition committee, which was formed to manage the transition and chief executive officer selection process.
In a separate action, Garrett was elected to Beckman Coulter's board of directors, effective January 17, 2005. The addition of Garrett to Beckman Coulter's board raises the number of directors from 11 to 12. Garrett will stand for election at the annual stockholder meeting in April 2006.
Prior to joining Beckman Coulter in 2002, Garrett served in several leadership positions in the biomedical and clinical diagnostics industries. He served as chief executive officer of Garrett Capital Advisors and as chief executive officer for Kendro Laboratory Products, L.P. His experience includes nearly 20 years with Baxter International/American Hospital Supply Corporation. As a member of Baxter's executive team, Garrett was instrumental in their spin-out of Dade International and led the new company to achieve success in its formative years.
Most read news
Other news from the department people
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.